-
August 7, 2020
Clinical Challenges: Platinum-Resistant Ovarian Cancer Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid Tumors Bookmark
George Lundberg, MDArticle from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.
Go to full article published by GenomeWeb.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 4, 2020
FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma Bookmark
Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.
The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.
Go to full article published by Novocure on Business Wire.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
July 11, 2020
Diffuse Midline Gliomas Bookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
This outline from the National Cancer Institute provides an overview of diffuse midline gliomas. Diffuse intrinsic pontine gliomas (DIPG), which occur primarily in children, are a subset of diffuse midline gliomas. -
June 8, 2020
New Treatments for Ovarian Cancer in 2020
Smruti Vidwans, PhDWomen with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read on to learn more about ovarian cancer and how it can be treated. What are the risk factors and symptoms of ovarian cancer? The American Cancer Society estimates that, in 2020, about 21,750 American… Read more »
-
May 30, 2020
China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Bookmark
George Lundberg, MDPress release from Novocure curated by Editor in Chief George Lundberg, MD, who notes:
Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.
Go to full article published by Novocure on Business Wire.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC Bookmark
George Lundberg, MDArticle from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Treatment Options
Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.
